In one study, targeted gene analysis of ctDNA showed high consistency in the levels of TMB between tissue and blood samples which were higher in TP53-mutated patients with advanced liver cancer, indicating that ctDNA analysis could be a better option to evaluate TMB prior to immunotherapy in cases of advanced primary liver cancers where tissue biopsy was not recommended [18]. Here, TP53 is linked to liver cancer.